C4 Therapeutics, Inc. announced strategic priorities and 2022 milestones to advance its targeted protein degradation portfolio. Advance multiple small molecule oncology degrader programs in the clinic to deliver a new generation of medicines that transforms patients' lives. CFT7455: CFT7455 is a novel degrader targeting IKZF1/3 for the treatment of multiple myeloma (MM) and non-Hodgkin's lymphomas (NHL), including peripheral T cell lymphoma and mantle cell lymphoma.

Present initial clinical data from Cohort A of the ongoing Phase 1/2 trial in relapsed or refractory MM and NHL at a medical meeting in 1H 2022. Progress the CFT7455 Phase 1/2 trial toward identifying a recommended Phase 2 dose for MM and NHL. CFT8634: CFT8634 is a degrader targeting BRD9 for the treatment of synovial sarcoma and SMARCB1-null solid tumors.

Initiate a Phase 1 trial in synovial sarcoma and SMARCB1-null solid tumors in 1H 2022. CFT1946: CFT1946 is a mutant-selective degrader of BRAF V600X for the treatment of V600 mutant solid tumors. Submit an investigational new drug (IND) application and begin a Phase 1 trial in BRAF V600X driven cancers including melanoma, colorectal and non-small cell lung (NSCLC) in 2H 2022.

CFT8919: CFT8919 is a potent and selective degrader of EGFR L858R for the treatment of NSCLC.